logo
What Is Nervous System Dysregulation?

What Is Nervous System Dysregulation?

Health Line08-05-2025
Your autonomic nervous system helps regulate emotional balance, but chronic stress or trauma can trigger an overactive fight-or-flight response.
Nervous system dysregulation refers to a condition in which the nervous system becomes overly sensitive and reactive. It primarily affects the autonomic nervous system, which governs involuntary bodily functions such as heart rate, breathing, temperature regulation, and digestion.
When the nervous system is dysregulated, it becomes imbalanced easily and remains in that imbalanced state for too long.
Aspects of autonomic nervous system function, such as digestion, blood pressure, heart rate, and sweating, change in response to stress.
An ongoing imbalance can have negative effects on both physical and mental health, influencing how we feel, think, and respond to the world around us.
Learn more about what nervous system dysregulation is, what causes it, the signs to look out for, and effective ways to restore balance and promote a sense of calm.
What happens during dysregulation?
During nervous system dysregulation, the body's natural ability to regulate internal functions becomes compromised. The autonomic nervous system has two main branches: the sympathetic and parasympathetic.
The , often known as the fight or flight system, prepares the body for action in response to physical or cognitive challenges or perceived threats
The parasympathetic branch, often called the rest and digest system, promotes relaxation and recovery.
In a healthy nervous system, these two branches work together to keep the body in a dynamic state of balance.
However, in a dysregulated state, the sympathetic system tends to dominate, keeping the body in a heightened state of alert even when no real danger is present. This can result in chronic stress responses and an inability to feel safe or calm.
Dysregulation can also manifest through parasympathetic dominance, leading to symptoms such as passivity, excessive sleep, low energy, and disengagement. Both patterns reflect an imbalance in the nervous system's ability to self-regulate.
Signs and symptoms
Some common signs that may indicate nervous system dysregulation include:
heightened sensitivity to noise, light, or other sensory input
difficulty managing emotional responses or mood changes
trouble falling or staying asleep
digestive issues, such as nausea or irritable bowel symptoms
persistent fatigue, even after adequate rest
anxiety or panic attacks
difficulty concentrating or feeling mentally foggy
It's important to note that the range and severity of symptoms can vary significantly from person to person. For instance,while some may experience mild signs like increased sweating, others may have more intense reactions such as palpitations, shortness of breath, or dizziness.
Primary causes
If you're noticing that you have features of nervous system dysregulation, it could be a symptom of an underlying health condition.
Chronic stress
When an individual experiences ongoing stress over a long period, the body may remain in a near-constant state of fight or flight.
This continual activation of the sympathetic nervous system can lead to a breakdown in the body's ability to self-regulate.
Trauma
Psychological or physical trauma can have a profound impact on the nervous system. Traumatic experiences, particularly those that occur in childhood or are repeated over time, can disrupt the typical development and function of the autonomic nervous system.
This can contribute to conditions such as post-traumatic stress disorder (PTSD), where dysregulation is a prominent feature.
Associated conditions
Nervous system dysregulation is increasingly being recognized in relation to several medical and psychological conditions:
Autism: Individuals with autism may experience nervous system dysregulation, which can affect sensory processing and emotional regulation. Heightened sensitivity to stimuli is a common feature of autism.
Mental health conditions: Disorders such as anxiety, depression, and borderline personality disorder often involve elements of dysregulation, with symptoms tied closely to difficulty managing emotional and physiological responses.
Sleep disorders: Disrupted sleep can both result from and contribute to nervous system dysregulation. Poor sleep affects the body's ability to recover and restore equilibrium, creating a cycle of imbalance.
Management approaches
There are several strategies that can help bring the autonomic nervous system back into balance. However, some causes, such as pituitary, adrenal, or thyroid disease, will also require medical treatment.
Practice mindfulness and deep breathing
Engaging in regular mindfulness practices, such as meditation, body scans, or simply focusing on your breath, can help activate the parasympathetic nervous system, which calms the body.
Techniques like box breathing (inhale for 4, hold for 4, exhale for 4, hold for 4) are especially effective in lowering heart rate and reducing feelings of anxiety or overwhelm. Just a few minutes a day can make a difference.
Move your body regularly
Physical movement helps discharge built-up stress and reconnects you to the present moment.
Activities like walking, gentle stretching, yoga, or dancing offer both physical release and sensory feedback, which supports nervous system regulation. Even brief movement breaks throughout the day can help you reset.
Seek professional support
A trained therapist, particularly one experienced in somatic therapies, trauma-informed care, or nervous system-focused approaches, can guide you through healing and r egulation techniques tailored to your needs.
Medical providers can also help identify or manage any physical conditions that may be contributing to nervous system dysregulation.
Make supportive lifestyle adjustments
Your daily habits play a big role in nervous system health. These habits can include:
establishing a consistent routine
getting quality sleep
reducing stimulants like caffeine or sugar
creating an environment that feels safe
These small, steady changes help signal to your nervous system that it's okay to relax.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Preclinical CRO Market Size at USD 6.8 Billion in 2025, Forecasted to Grow at 8.73% CAGR Through 2034
Preclinical CRO Market Size at USD 6.8 Billion in 2025, Forecasted to Grow at 8.73% CAGR Through 2034

Yahoo

time17 minutes ago

  • Yahoo

Preclinical CRO Market Size at USD 6.8 Billion in 2025, Forecasted to Grow at 8.73% CAGR Through 2034

The global preclinical CRO market size is calculated at USD 6.80 billion in 2025 and is expected to reach around USD 14.34 billion by 2034, growing at a CAGR of 8.73% for the forecasted period. Ottawa, July 16, 2025 (GLOBE NEWSWIRE) -- The global preclinical CRO market size was valued at USD 6.25 billion in 2024 and is predicted to hit around USD 14.34 billion by 2034, a study published by Towards Healthcare a sister firm of Precedence Research. Get a quick preview of key insights and trends shaping the preclinical CRO market: The growth of the market is driven by the major pharmaceutical companies and increased research and development in the developing regions, furthering the growth of the market. Key Takeaways North America led the global market with the highest market share of 48% in 2024. Asia Pacific is expected to grow at the fastest CAGR over the forecast period, 2025 to 2034. By service, the toxicology testing segment accounted for the largest revenue share in the global preclinical CRO market in 2024. By service, the bioanalysis and DMPK studies segment is anticipated to grow at the fastest rate during the forecast period. By model type, the patient-derived organoid (PDO) model segment held the largest share in 2024. By model type, the patient-derived xenografts (PDXs) model segment is expected to expand at a significant CAGR throughout the forecast period. By end use, the biopharmaceutical companies segment held the largest shares in 2024. By end-use, the government and academic institutes segment is expected to register the fastest growth during the forecast period. Preclinical CRO Market Overview & Potential A preclinical CRO (Contract Research Organization) offers vital research services mainly during the early, preclinical stage of developing drugs and medical devices, before human trials start. These organizations perform studies, including lab and animal testing, to assess the safety, effectiveness, and pharmacological characteristics of new treatments or devices. This critical phase gathers necessary data for regulatory filings such as Investigational New Drug (IND) applications and ensures safety before human testing. Preclinical CROs are essential in the initial development phases by delivering testing, data collection, and regulatory assistance, thereby supporting the progress of new therapies and medical innovations. Access detailed market data, segment breakdowns, and growth projections in one place: What Are the Key Growth Factors Responsible for The Growth of The Preclinical CRO Market? The key growth drivers responsible for the growth of the market are the increased complexity and cost of drug development, rising prevalence of chronic diseases, regulatory stringency, and advanced technological advancements are the key growth drivers which help in the growth of the market. The growth of the biotechnology sector, with its focus on biologics, cell and gene therapies, and other advanced therapies, is in increasing demand. The increased research and development by the pharmaceutical and biotechnology companies further boost the growth of the market, supporting the expansion. What Are the Growing Trends Associated with The Preclinical CRO Market? Advancements in Technology The technological advancements, like the integration of AI, high-throughput screening, and in vivo imaging to enable more efficient and personalized research, are a growing trend. Increased Outsourcing Increasing outsourcing by pharmaceutical and biotech companies to leverage specialized expertise, reduce costs, and accelerate drug development fuels the growth. Focus on Specialized Services The growing demand for specialized services like personalized medicines and biologics, and testing procedures further drives the growth of the market. Growing Demand for CROs The growing demand to enhance and improve efficiency for substantial growth in the market and testing boosts the demand. What Is the Growing Challenge in The Preclinical CRO Market? The key challenge that limits the growth of the market is the regulatory hurdles, like complex compliance, time-consuming approvals, data integrity maintaining high data quality in large-scale research is a challenge which hinders the growth of the market. The cost and complexity of maintaining quality and reliability are a major challenge that hinders the growth of the market. You can place an order or ask any questions, please feel free to contact us at sales@ Regional Analysis How Did North America Dominate the Preclinical CRO Market In 2024? North America led the global market with the highest market share of 48% in 2024. The growth of the market is driven by the increasing research and development investments, the rising prevalence of chronic diseases, and the presence of large major pharmaceutical and biotechnology companies, which fuel the growth of the market in the region. The well-established healthcare infrastructure and strong presence of major companies like Charles River Laboratories, LabCorp Drug Development, and Eurofins Scientific further fuel the growth of the market. The growth of the market is also driven by increased cost reduction and the ongoing development in therapeutic areas like gene therapy and neurodegenerative diseases, further fueling the growth of the market and supporting its expansion of the market. Preclinical CROs in the U.S. are expanding rapidly due to rising demand for faster, cost-effective drug development. These organizations offer specialized services in toxicology, pharmacology, and bioanalysis, helping streamline R&D pipelines. Technological advancements and regulatory complexities are driving sponsors to outsource, fostering deeper collaborations and innovation within the life sciences sector. Canada's preclinical CRO sector is scaling rapidly, notably in Ontario and Quebec. Providers like BenchSci (AI-enabled target screening) and IonsGate (expanded toxicology services) enhance provincial R&D pipelines. Altasciences' Mississauga labs handle diverse in vivo models. Partnerships with Health Canada and CIHR grants support facility expansion and deeper pharma-CRO cooperation. Elevate your healthcare strategy with Towards Healthcare. Enhance efficiency and drive better outcomes schedule a call today: What Made Asia Pacific Significantly Grow in The Preclinical CRO Market In 2024? Asia Pacific is expected to grow at the fastest CAGR over the forecast period, 2025 to 2034. The growth of the market is driven by the offering of cost-effectiveness of research and development and the offering of effective solutions for preclinical research, which attracts national and international pharmaceutical companies for investments, which increases the growth of the market in the region. The growth is also driven by the expanding biopharma companies, and expanding research also demands and needs preclinical CRO services. Additionally, advancements in personalized medicines and oncology research in the region, with government support and infrastructure due to an increase in clinical trials, drive significant growth and expansion of the market in the region. Chinese preclinical CROs led by giants like WuXi AppTec and Pharmaron have built globally compliant GLP labs in Suzhou, Shanghai, and Wuhan. They now offer advanced in vivo ADME/Tox, NHP models, isotope-based DMPK, and continuous-infusion rodent studies. High-tech-park clusters and regulatory accreditation drive international-grade services. India's preclinical CRO landscape is expanding in Hyderabad, Bengaluru, and Pune. Providers like GVK Bio and Jubilant Biosys operate GLP-certified toxicology and pharmacology labs. Emerging capabilities include canine and NHP models, PK/PD biomarker development, whole-body autoradiography, and AI-assisted data analytics. Collaborations with DST and DBT bolster translational study infrastructure. Segmental Insights By service How Did Service Segment Dominate the Preclinical CRO Market In 2024? The toxicology testing segment accounted for the largest revenue share in the global market in 2024. Toxicology testing services in the market play a vital role in assessing the safety profile of new drug candidates before they enter clinical trials. These services help identify potential toxic effects on different organs and systems, ensuring regulatory compliance and minimizing risks to human health. With increasing drug development activities and stringent safety regulations, demand for reliable toxicology testing is growing rapidly. This supports the expansion of preclinical CRO services, enabling pharmaceutical and biotech companies to advance their pipelines efficiently and safely. The bioanalysis and DMPK studies segment is anticipated to grow at the fastest rate during the forecast period. Bioanalysis and DMPK (Drug Metabolism and Pharmacokinetics) studies are essential services offered by preclinical CROs to evaluate the absorption, distribution, metabolism, and excretion of drug candidates. These studies provide crucial data on drug behaviour in the body, guiding dose selection and safety assessments before clinical trials. The growing need for precise pharmacokinetic data to meet regulatory requirements and optimize drug design fuels the demand for these services, supporting market growth and accelerating drug development timelines for pharmaceutical companies. By model type Which Patient-Derived Organoid Model Segment Dominated the Preclinical CRO Market In 2024? The patient-derived organoid (PDO) model segment held the largest share in 2024. Patient-derived organoid models in the preclinical CRO market are gaining significant attention due to their ability to closely mimic human tissue and tumor microenvironments. These 3D models, developed from patient-specific cells, enable more accurate prediction of drug responses and toxicity compared to traditional models. They support personalized medicine approaches and improve the success rate of drug candidates by providing better translational relevance. The increasing demand for more precise and human-relevant models drives the adoption of patient-derived organoids, fueling market growth. The patient-derived xenografts (PDXs) model segment is expected to expand at a significant CAGR throughout the forecast period. Patient-derived xenograft (PDX) models are increasingly used in the preclinical CRO market due to their high predictive value for human clinical outcomes. In these models, tumor tissues from patients are implanted into immunodeficient mice, preserving the original tumor's characteristics and heterogeneity. PDX models enable researchers to study tumor behavior, evaluate drug efficacy, and identify potential biomarkers more accurately. The rising focus on personalized medicine and the need for clinically relevant data drive demand for PDX models, supporting market expansion. By end use Which End Use Segment Dominated the Preclinical CRO Market In 2024? The biopharmaceutical companies segment held the largest shares in 2024. Biopharmaceutical companies are major end users in the preclinical CRO market, relying heavily on these services to accelerate and streamline their drug development pipelines. By outsourcing preclinical studies such as toxicology, bioanalysis, DMPK, and efficacy testing, these companies reduce costs, minimize risks, and access specialized expertise and advanced models. This enables them to focus on core research activities and bring innovative therapies to market faster. The growing emphasis on biologics and complex molecules further fuels demand, driving market growth and expansion. The government and academic institutes segment is expected to register the fastest growth during the forecast period. Government and academic institutes play a crucial role as end users in the preclinical CRO market, utilizing outsourced research services to advance scientific knowledge and support public health initiatives. These institutions often engage CROs for specialized studies, including safety evaluations, mechanistic research, and early-stage drug discovery, due to limited in-house resources or expertise. Their focus on translational research, new therapeutic approaches, and regulatory science drives the demand for high-quality preclinical services, supporting market growth and healthcare innovation. Get the latest insights on life science industry segmentation with our Annual Membership: Recent Developments In April 2025, Debiopharm Research & Manufacturing S.A., a Swiss-based global biopharmaceutical company, launched a license agreement for the use of the AbYlink™ technology for preclinical services. In November 2024, Thermo Fisher Scientific launched a suite of expanded CRO and CDMO services under its brand. The company has introduced to the market its Accelerator™ Drug Development, which Thermo Fisher is marketing as '360°' CDMO and CRO drug development solutions. Top Companies and Their Contributions to the Preclinical CRO Market Company Key Contributions and Offerings WuXi AppTec Offers end-to-end preclinical services in toxicology, pharmacology, and DMPK; strong in IND-enabling studies and global regulatory compliance. Pharmaceutical Product Development (PPD) Specializes in nonclinical safety studies, ADME, and bioanalytical services; strong support for early-phase compound selection and optimization. Medpace, Inc. Provides integrated preclinical trial design and execution; strengths in pharmacokinetics, toxicology, and disease models, particularly in oncology and cardiology. Charles River Laboratories Industry leader in in vivo and in vitro safety assessments, genetic toxicology, and pathology; offers extensive animal model capabilities. PRA Health Sciences Known for translational medicine and biomarker development, it combines lab and clinical data to enhance candidate evaluation. PAREXEL Delivers regulatory consulting, toxicology, and pathology services; known for integrating preclinical findings into clinical strategy. Envigo Offers regulatory toxicology, safety pharmacology, and metabolism studies; robust capabilities in GLP and non-GLP environments. Eurofins Scientific Provides comprehensive testing services including genotoxicity, ecotoxicology, and bioanalytics; also specializes in agrochemical safety. LabCorp (Covance) Delivers large-scale preclinical services in drug metabolism, bioanalytical chemistry, and regulatory toxicology. ICON Plc Offers early-phase lab services including preclinical feasibility studies, assay development, and integrated biomarker strategies. Browse More Insights of Towards Healthcare: The global medical device CRO market was valued at USD 8.49 billion in 2024 and increased to USD 9.25 billion in 2025. It is expected to reach USD 19.9 billion by 2034, growing steadily at a CAGR of 8.98% from 2025 to 2034. The biopharmaceuticals CRO market is showing strong growth and is expected to generate significant revenue, reaching hundreds of millions of dollars between 2025 and 2034. The global healthcare CRO market was valued at USD 53.87 billion in 2024, grew to USD 57.66 billion in 2025, and is projected to reach USD 106.25 billion by 2034, growing at a CAGR of 7.04% over the forecast period. The pharma CRO services market is expected to grow from USD 36.66 billion in 2025 to USD 87.03 billion by 2034, with a healthy CAGR of 10.04% from 2025 to 2034. The preclinical advanced cell models market is also expanding rapidly and is forecasted to earn hundreds of millions in revenue between 2025 and 2034. The global mRNA therapeutics CDMO market grew from USD 4.62 billion in 2024 to USD 5.15 billion in 2025, and is projected to reach USD 13.63 billion by 2034, growing at a CAGR of 11.37%. The drug discovery as a service market was worth USD 21.3 billion in 2024, rose to USD 24.32 billion in 2025, and is expected to reach USD 79.82 billion by 2034, growing at a robust CAGR of 14.17%. The CDMO services market for pharma and biotech is experiencing significant growth between 2024 and 2034, driven by a strong shift toward outsourcing by these industries. The global cell culture media market increased from USD 6.9 billion in 2024 to USD 7.69 billion in 2025, and is projected to reach USD 20.32 billion by 2034, growing at a CAGR of 11.45%. The small molecule CDMO market was valued at USD 72.81 billion in 2024, reached USD 78.01 billion in 2025, and is forecasted to hit USD 145.12 billion by 2034, growing at a CAGR of 7.14%. Key Players List of Preclinical CRO Market Wuxi AppTec Pharmaceutical Product Development Medpace, Inc. Charles River Laboratories International, Inc. PRA Health Science, Inc. PAREXEL Envigo Eurofins Scientific Laboratory Corporation of America ICON Plc Intertek Group Plc (IGP) LABCORP Crown Bioscience PPD (Thermo Fisher Scientific, Inc.) Segments Covered in the Report By Service Bioanalysis and DMPK studies In vitro ADME In vivo PK Toxicology Testing GLP Non-GLP Compound Management Process R&D Custom Synthesis Others Chemistry Medicinal Chemistry Computational Chemistry Safety Pharmacology Others By Model Type Patient-Derived Organoid (PDO) Model Patient-derived xenograft model By End-use Biopharmaceutical Companies Government and Academic Institutes Medical Device Companies By Region North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Unlock the complete preclinical CRO market analysis, with strategic insights and expert forecasts: You can place an order or ask any questions, please feel free to contact us at sales@ Gain access to the latest insights and statistics in the healthcare industry by subscribing to our Annual Membership. Stay updated on healthcare industry segmentation with detailed reports, market trends, and expert analysis tailored to your needs. Stay ahead of the curve with valuable resources and strategic recommendations. Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare: Get a Subscription About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. Our Trusted Data Partners Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire For Latest Update Follow Us: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Denny's Teams Up with Cookies for Kids' Cancer to ‘Strike Out' Pediatric Cancer
Denny's Teams Up with Cookies for Kids' Cancer to ‘Strike Out' Pediatric Cancer

Yahoo

time17 minutes ago

  • Yahoo

Denny's Teams Up with Cookies for Kids' Cancer to ‘Strike Out' Pediatric Cancer

America's Diner launches national partnership to help fund breakthrough cancer research, donating proceeds from Kids' menu and limited-edition T-shirt Denny's and Cookies for Kid's Cancer team up to raise funds for pediatric cancer research. Denny's and Cookies for Kid's Cancer team up to raise funds for pediatric cancer research. Spartanburg, SC, July 16, 2025 (GLOBE NEWSWIRE) -- Denny's is adding to their partnership with Cookies for Kids' Cancer, a leading nonprofit organization committed to raising funds for pediatric cancer, with a new way that everyone can help. For 16 years, Denny's has supported Cookies for Kids' Cancer on a regional level, raising nearly $1.5 million to fund research for new, improved treatments. The expanded nationwide partnership will drive progress for kids who deserve 'More time, more options, and a future beyond cancer.' In true Grand Slam® fashion, Denny's has launched a limited-edition 'Let's Strikeout Kids' Cancer' T-shirt, available now at All proceeds from the shirt sales will benefit Cookies for Kids' Cancer. In addition, Denny's is supporting the cause through its menu: for every Kids' menu item sold now through Spring of 2026, a portion of the proceeds will be donated to help fight pediatric cancer. And lastly, guests can also contribute by rounding up their checks to support fundraising efforts now through August 26, 2025. 'At our core, we love to feed people and serve families in our communities, which includes those directly impacted by pediatric cancer. A diagnosis can happen to any family at any time. I know this too well, as I lost my brother to cancer at a young age,' said Chris Bode, president and chief operating officer of Denny's. 'There's still so much work to be done to find a cure. Together with Cookies for Kids' Cancer, we will fund meaningful progress and get one step closer to ending the disease once and for all.' 'With Denny's nationwide presence, we can raise critical awareness and funds for pediatric cancer, the leading cause of death by disease in children. Denny's guests likely know a child affected, and the concept of being a 'Good Cookie' is something we think every Denny's guest can embrace,' said Gretchen Witt, co-founder and executive director. 'Our collaboration will directly boost the number of research grants we can fund, which lead to new treatment options and real hope for families. In fact, the very first treatment we helped to fund became available seven months after my son Liam lost his battle and has since helped countless kids.' Guests looking to support Cookies for Kids' Cancer can head to their local Denny's, as every visit helps. Guests can also grab their very own 'Let's Strikeout Kids' Cancer' T-shirt *while supplies last at To learn more, visit ### About Denny's Corp Denny's is a Spartanburg, S.C. - based family dining restaurant brand that has been welcoming guests to our booths for more than 70 years. Our guiding principle is simple: We love to feed people. Denny's provides craveable meals at a meaningful value across breakfast, lunch, dinner, and late night. Whether it's at our brick-and-mortar locations, via Denny's on Demand (the first delivery platform in the family dining segment), or at The Meltdown, Banda Burrito, and The Burger Den, our three virtual restaurant concepts, Denny's is ready to delight guests whenever and however they want to order. Our longstanding commitment to supporting our local communities in need is brought to life with our Mobile Relief Diner (that delivers hot meals to our neighbors during times of disaster), Denny's Hungry for Education™ scholarship program, our annual fundraiser with long-time-partner No Kid Hungry, and our new partnership supporting Cookies for Kids' Cancer in their mission to fund research for new, improved and less toxic treatments for kids facing cancer. Denny's is one of the largest franchised full-service restaurant brands in the world, based on the number of restaurants. As of March 26, 2025, the Denny's brand consisted of 1,491 restaurants, 1,430 of which were franchised and licensed restaurants and 61 of which were company-operated. This includes 166 restaurants in Canada, Costa Rica, Curacao, El Salvador, Guam, Guatemala, Honduras, Indonesia, Mexico, New Zealand, the Philippines, Puerto Rico, the United Arab Emirates, and the United Kingdom. To learn more about Denny's, please visit our brand website at or the brand's social channels via Facebook, Instagram, LinkedIn or YouTube. About Cookies for Kids' CancerCookies for Kids' Cancer is a nationally recognized 501(c)(3) nonprofit organization dedicated to funding research for new, improved and less toxic treatments for pediatric cancer—the #1 disease killer of children in the U.S. Inspired by the belief that everyone can make a difference, the organization mobilizes individuals, businesses, and communities to raise critical funding through grassroots events like bake sales, fitness challenges, and corporate campaigns. Since its founding, Cookies for Kids' Cancer has granted more than $23 million, supporting over 140 cutting-edge research projects and contributing to 60 new treatment options. Backed by a global network of 18,000+ passionate supporters, every dollar donated is tax-deductible and fuels hope for children fighting cancer. Attachments Denny's and Cookies for Kid's Cancer team up to raise funds for pediatric cancer research. Denny's and Cookies for Kid's Cancer team up to raise funds for pediatric cancer research. CONTACT: Denny's Media Team Denny's 864-597-8005 media@

New Cadent Study Finds TV Ads Rival Doctors in Driving Awareness of New Medications Across Key Demographics
New Cadent Study Finds TV Ads Rival Doctors in Driving Awareness of New Medications Across Key Demographics

Yahoo

time17 minutes ago

  • Yahoo

New Cadent Study Finds TV Ads Rival Doctors in Driving Awareness of New Medications Across Key Demographics

More than half of Americans find new medications through CTV and linear ads, according to recent data in pharmaceutical advertising NEW YORK, July 16, 2025 /PRNewswire/ -- Cadent, the predictive advertising company, today announced findings from its new study, Cadent Pharma Advertising Trends, fielded with The Harris Poll. The findings revealed that while doctors and healthcare providers remain the primary source for respondents to learn about new medications (68%), TV and connected TV (CTV) ads are gaining traction, at 62%. The study surveyed over 4,000 US consumers to achieve a more inclusive understanding of healthcare perceptions. With a focus on the impact of pharma advertising on multicultural groups, the survey explored trends within Hispanic, Black, White, and Asian demographics. "Harnessing the power of CTV and cross-screen advertising is crucial for pharmaceutical advertisers," said Bradley Deutsch, SVP at Cadent Health. "Seventy-six percent of consumers are more inclined to take action after encountering an ad across multiple devices. These platforms don't just introduce new medications–they are a critical factor for driving brand awareness and engagement throughout the patient journey, encouraging consumers to discuss the advertised medications with their healthcare providers." More findings from the report include: CTV tops linear TV for Hispanic Americans: Hispanic Americans are more likely to discover prescription medicines from ads on CTV (33%) than ads on linear TV (28%). Mobile ads drive action: After seeing a medication ad on mobile, 73% of Americans reported being likely to ask their doctor about a prescription medication, research an over-the-counter medication (71%), and buy over-the-counter medications (64%). Black Americans are most comfortable with AI-generated ad campaigns: 61% of Black Americans are comfortable with targeted online ads featuring AI-generated content, followed by 57% of Hispanic Americans. Only 38% of White Americans and 37% of Asian Americans are in agreement. QR codes capture attention: Nearly half (47%) of Americans are inclined to scan a QR code for more details after viewing a medication ad on CTV. Among them, Black Americans lead at 68%, followed by Hispanic Americans at 63%, Asian Americans at 44%, and White Americans at 40%. "Given the evolving landscape and the potential shifts in how pharmaceutical advertisements are delivered, understanding where your audience is engaging and how to connect with them is more critical than ever," continued Bradley Deutsch, SVP at Cadent Health. "Pharmaceutical advertisers can effectively reach and engage their target audience by leveraging these insights—without compromising individual privacy. Trust and education are key drivers of engagement, particularly in healthcare, where consumers increasingly value informative, relevant content. Highlighting specific demographics empowers marketers to create culturally relevant and educational campaigns that not only resonate with diverse audiences, but also foster trust—ensuring no one is left behind in healthcare communication." To learn more about Cadent or to download the full report, visit About CadentCadent ignites seamless connections between brands, publishers and consumers. Our advanced predictive models orchestrate outcomes on any platform customers are on, across any media they consume, and at any stage of their journey. Through our transparent, enterprise-class platform that adapts in real time and connects with hundreds of partners, we drive measurable outcomes across every screen. Learn more at About The Harris PollThe Harris Poll is one of the longest running surveys in the U.S. tracking public opinion, motivations and social sentiment since 1963 that is now part of Harris Insights & Analytics, a global consulting and market research firm that delivers social intelligence for transformational times. We work with clients in three primary areas; building twenty-first-century corporate reputation, crafting brand strategy and performance tracking, and earning organic media through public relations research. Our mission is to provide insights and advisory to help leaders make the best decisions possible. To learn more, please visit View original content to download multimedia: SOURCE Cadent

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store